Neurocrine Biosciences Presents INGREZZA Capsules Data On Tardive Dyskinesia Improvement Regardless Of Baseline Antipsychotic Use At 2023 Psych Congress Elevate
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences presented data from a meta-analysis of three long-term studies on INGREZZA capsules, showing substantial and sustained improvements in tardive dyskinesia (TD) in adults with or without concomitant antipsychotic therapy. The data were presented at the 2023 Psych Congress Elevate.
June 02, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences' INGREZZA data shows significant improvements in tardive dyskinesia, potentially boosting the company's stock price.
The positive data from the meta-analysis of three long-term studies on INGREZZA capsules demonstrates the effectiveness of the treatment in managing tardive dyskinesia, regardless of antipsychotic use. This could lead to increased demand for the product and potentially boost Neurocrine Biosciences' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100